5 completed, 5 terminated, 3 recruiting, 1 unknown. 5 Phase 4, 4 Phase 3, 3 Not applicable, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Terminated 2, Completed 1, Recruiting 1, Unknown 1 |
| Phase 3 | 4 | Completed 2, Terminated 2 |
| Not applicable | 3 | Recruiting 2, Completed 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Apixaban 2.5 MG: new trials by email Literature Review of Apixaban 2.5 MG trials Research Report on Apixaban 2.5 MG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS Apixaban 2.5 MG - Cirrhosis, Splenectomy | Not applicable | Recruiting | Northern Jiangsu People's Hospital | 20 | 2026-04-01 | 2026-03-31 |
| Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD Apixaban 2.5 MG - Cirrhosis, Splenectomy | Not applicable | Recruiting | Northern Jiangsu People's Hospital | 20 | 2026-04-01 | 2026-03-31 |
| Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial Apixaban 2.5 MG - Venous Thromboembolism, Bleeding | Phase 4 | Recruiting | Clinical Urology and Epidemiology Working Group | 5436 | 2024-06-06 | 2025-05-28 |
| Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection Apixaban 2.5 MG, Dipyridamole 25Mg Tab, subcutaneous Low Molecular Weight Heparin - Cirrhosis, Splenectomy | Not applicable | Completed | Northern Jiangsu People's Hospital | 40 | 2022-04-01 | 2023-12-21 |
| Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 Apixaban 2.5 MG, Placebo - Covid19, Thrombosis | Phase 4 | Terminated | Brazilian Clinical Research Institute | 411 | 2021-03-04 | 2022-08-25 |
| Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism Apixaban 2.5 MG, Placebo oral tablet - Deep Vein Thrombosis, Pulmonary Embolism | Phase 4 | Completed | Brigham and Women's Hospital | 600 | 2021-03-01 | 2025-11-14 |
| COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis Apixaban 2.5 MG, Placebo - Covid19 | Phase 3 | Completed | Thomas L. Ortel | 1291 | 2021-02-15 | 2025-02-25 |
| COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Apixaban 2.5 MG, Apixaban 5MG, Aspirin - COVID-19 | Phase 3 | Terminated | Frank C Sciurba | 657 | 2020-09-07 | 2022-02-17 |
| PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban Apixaban 5 MG, Apixaban 2.5 MG, Warfarin - Aortic Valve Disease, Aortic Valve Stenosis | Phase 3 | Terminated | Artivion Inc. | 863 | 2020-05-01 | 2024-03-20 |
| Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access Apixaban 2.5 MG, Active Control - Hemodialysis Access Failure | Phase 4 | Unknown | National Taiwan University Hospital Hsin-Chu Branch | 150 | 2020-03-14 | 2020-07-28 |
| Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs Apixaban 2.5 MG - Venous Thromboembolism | Phase 2 | Terminated | Instituto de Investigacion Sanitaria La Fe | 60 | 2019-04-12 | 2021-02-15 |
| API-CAT STUDY for APIxaban Cancer Associated Thrombosis Apixaban 5 MG - Cancer-associated Thrombosis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 1766 | 2018-10-11 | 2025-02-06 |
| Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism Warfarin, Apixaban 2.5 MG, Rivaroxaban 10 MG - Venous Thromboembolism | Phase 4 | Terminated | Duke University | 44 | 2018-08-01 | 2019-12-13 |
| A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery JNJ-64179375 0.3 mg/kg, JNJ-64179375 0.6 mg/kg, JNJ-64179375 1.2 mg/kg - VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery | Phase 2 | Completed | Janssen Research & Development, LLC | 308 | 2017-11-13 | 2019-11-25 |
Venous Thromboembolism (4) · COVID-19 (3) · Fibrosis (3) · Hypertension, Portal (3) · Thrombosis (3) · Venous Thrombosis (3) · Pulmonary Embolism (2) · Aortic Valve Disease (1) · Aortic Valve Stenosis (1) · Hemorrhage (1) · Hypersplenism (1) · Multiple Myeloma (1) · Neoplasms (1)
Northern Jiangsu People's Hospital (3) · Artivion Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Brazilian Clinical Research Institute (1) · Brigham and Women's Hospital (1) · Clinical Urology and Epidemiology Working Group (1) · Duke University (1) · Frank C Sciurba (1) · Instituto de Investigacion Sanitaria La Fe (1) · Janssen Research & Development, LLC (1) · National Taiwan University Hospital Hsin-Chu Branch (1) · Thomas L. Ortel (1)
United States (6) · China (3) · Spain (3) · Belgium (2) · Brazil (2) · Canada (2) · Italy (2) · Poland (2) · Argentina (1) · Austria (1) · Bulgaria (1) · Finland (1) · France (1) · Greece (1) · Japan (1)
Dou-Sheng Bai (2) · Frank Sciurba (1) · Guy Meyer, Pr (1) · Javier de la Rubia (1) · John Alexander, MD (1) · Kari AO Tikkinen, Professor (1) · Lars Svensson, MD, PhD (1) · Ping Chen, MD (1) · Renato D. Lopes, MD, PhD (1) · Samuel Romero (1) · Thomas Ortel, MD (1) · Tracy Wang, MD (1)
PMID 37591523, PMID 34473343, PMID 34633405, PMID 36940444, PMID 37189091, PMID 37489818, PMID 38320162, PMID 40162636, PMID 40888734, PMID 41365312, PMID 42361291
2016 (1), 2023 (1)